AU2018329628B2 - Pridopidine for treating drug induced dyskinesias - Google Patents

Pridopidine for treating drug induced dyskinesias Download PDF

Info

Publication number
AU2018329628B2
AU2018329628B2 AU2018329628A AU2018329628A AU2018329628B2 AU 2018329628 B2 AU2018329628 B2 AU 2018329628B2 AU 2018329628 A AU2018329628 A AU 2018329628A AU 2018329628 A AU2018329628 A AU 2018329628A AU 2018329628 B2 AU2018329628 B2 AU 2018329628B2
Authority
AU
Australia
Prior art keywords
pridopidine
subject
levodopa
day
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018329628A
Other languages
English (en)
Other versions
AU2018329628A1 (en
Inventor
Michal Geva
Michael Hayden
Aric ORBACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of AU2018329628A1 publication Critical patent/AU2018329628A1/en
Application granted granted Critical
Publication of AU2018329628B2 publication Critical patent/AU2018329628B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018329628A 2017-09-08 2018-08-30 Pridopidine for treating drug induced dyskinesias Active AU2018329628B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US62/556,314 2017-09-08
US201862649184P 2018-03-28 2018-03-28
US62/649,184 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
AU2018329628A1 AU2018329628A1 (en) 2020-04-16
AU2018329628B2 true AU2018329628B2 (en) 2021-04-22

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018329628A Active AU2018329628B2 (en) 2017-09-08 2018-08-30 Pridopidine for treating drug induced dyskinesias

Country Status (10)

Country Link
US (2) US20190231768A1 (OSRAM)
EP (1) EP3678664A1 (OSRAM)
JP (1) JP2020533296A (OSRAM)
CN (1) CN111343982A (OSRAM)
AU (1) AU2018329628B2 (OSRAM)
BR (1) BR112020004622A2 (OSRAM)
CA (1) CA3075020C (OSRAM)
IL (1) IL273044A (OSRAM)
MX (1) MX383462B (OSRAM)
WO (1) WO2019050775A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
KR20250021199A (ko) 2023-08-03 2025-02-12 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428822A2 (en) * 1999-12-22 2004-06-16 A. Carlsson Research AB 1-phenylpiperazine derivative as modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
JP5393654B2 (ja) 2007-04-12 2014-01-22 イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
WO2015138130A1 (en) 2014-03-10 2015-09-17 Applied Materials, Inc. Pixel blending for multiple charged-particle beam lithography
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
CA3015512C (en) 2016-02-24 2024-01-16 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
WO2018053287A1 (en) 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
AU2018210145B2 (en) 2017-01-20 2023-06-29 Agency For Science, Technology And Research Use of pridopidine for the treatment of fragile X syndrome
BR112020003119A2 (pt) 2017-08-14 2020-10-13 Prilenia Neurotherapeutics Ltd. método de tratamento de esclerose lateral amiotrófica com pridopidina
EP3675830A1 (en) * 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428822A2 (en) * 1999-12-22 2004-06-16 A. Carlsson Research AB 1-phenylpiperazine derivative as modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PONTEN HENRIK et al.: "The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model", EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, vol. 698, no. 1-3, pages 278 - 285 *

Also Published As

Publication number Publication date
MX2020002645A (es) 2021-06-10
US20190231768A1 (en) 2019-08-01
US11000519B2 (en) 2021-05-11
CA3075020A1 (en) 2019-03-14
IL273044A (en) 2020-04-30
MX383462B (es) 2025-03-14
US20190350914A1 (en) 2019-11-21
WO2019050775A1 (en) 2019-03-14
EP3678664A1 (en) 2020-07-15
CA3075020C (en) 2021-12-07
CN111343982A (zh) 2020-06-26
BR112020004622A2 (pt) 2020-09-24
AU2018329628A1 (en) 2020-04-16
JP2020533296A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
AU2018329628B2 (en) Pridopidine for treating drug induced dyskinesias
Baldessarini et al. Pharmacotherapy of psychosis and mania
Pahwa et al. New antipsychotic medications in the last decade
CA2500662A1 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
MX2015003812A (es) Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
JP2023523569A (ja) 神経学的および精神障害の治療方法
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
US20200323823A1 (en) Methods for the treatment of depression
Monti The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder
WO2009128058A1 (en) Psycho-pharmaceuticals
JP2017519827A (ja) ブスピロン代謝産物の使用
US20200129455A1 (en) Composition and method for treating neurological disease
CN117177741A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合
US20190247327A1 (en) Composition and method for treating neurological disease
WO2020110128A1 (en) Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US20240197756A1 (en) Methods of treatment with neuroactive steroids
US12036213B2 (en) Pridopidine for treating drug induced dyskinesias
HUP0101341A2 (hu) Új gyógyszer-kombinációk
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response Patterns
WO2012072665A1 (en) Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
HK1036592A (en) New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)